|  |
| --- |
| **BIOGRAPHICAL SKETCH**Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.Follow this format for each person.  **DO NOT EXCEED FOUR PAGES.** |
|  |
| NAME**Ralph L. Henry** | POSITION TITLE**Distinguished Professor** |
| eRA COMMONS USER NAME |
| EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)* |
| INSTITUTION AND LOCATION | DEGREE*(if applicable)* | YEAR(s) | FIELD OF STUDY |
| University of Kansas, Lawrence KS | BSE | 1979-1984 | Biology and Chemistry |
| Kansas State University, Manhattan KS | MS | 1984-1987 | Plant Physiology |
| Kansas State University, Manhattan KS | PhD | 1987-1991 | Membrane protein assembly |
| University of Florida, Gainesville FL | Postdoctoral | 1992-1996 | Protein targeting |

**PROFESSIONAL EXPERIENCE**

2004-present VP Biopharmaceutics, InterveXion Therapeutics, LLC

2012-present Distinguished Professor, Biological Sciences Dept., Univ. of Arkansas

2005-present Professor, Biological Sciences Dept., University of Arkansas

2002-2005 Associate Professor, Biological Sciences Dept., Univeristy of Arkansas

1996-2002 Assistant Professor, Biological Sciences Dept., University of Arkansas

**OTHER RELEVENT PROFESSIONAL EXPERIENCES**

* **Grant Review Panel Member, National Science Foundation**,

Spring 2001, Fall 2010, Fall 2013.

* **Grant Review Panel Member, Department of Energy (Bio-Energy Sciences)**,

Fall 2004, Fall 2007, Spring 2011, Spring 2014.

* **Grant Review Panel Member, National Institutes of Health**,

Spring 2003.

* **Chair, Conference Organizing Committee,** Conference on Nanotechnologgy for Healthcare, April 6-9, 2011; Winthrop Rockefeller Institute, Petit Jena Mountain, AR.
* **Presenter to FDA:** Pre-Investigational New Drug application, submitted by InterveXion Therapeutics (September, 2009 and April, 2011).
* **Oversight of cGMP antibody production** for InterveXion Therapeutics’ animal toxicology and Phase 1 clinical trial (Jan. 2010-.July 2011).
* **Outside Consultant:** Biotechnology Investment Group, Third Security, San Francisco, CA (July, 2009).
* **U. of A. Nanoscience Institute Steering Committee**, member (2007-present)

**HONORS and AWARDS**

* **WM Keck Endowed Professorship**, Awarded February, 2013
* **Inaugural member National Academy of Inventors,** May 2013
* **Fellow, South East Conference Academic Leadership Program (**2009**-**2010)

**HONORS and AWARDS (Continued)**

* **Panel Moderator**; NSF National Conference, Trajectory Toward Sustainable Scientific Based Success in EPSCoR Jurisdiction, *Panel on Biotechnology Initiatives.* September 2005, Porto Rico.
* **Panel Moderator**: Arkansas Venture Forum, Nanotechnology in Medicine and Life Sciences, November 2006, Rogers AR
* **Session Leader:** Department of Energy Investigators Conference, November 3-6 2011, Baltimore MD.
* **Session Leader:** Gordon Research Conference on Protein Transport Across Cell Membranes, March 11-16 2012, Galveston TX.
* **Initiated Into Membership,** National Academy of Inventors**,** May 2013

**PATENTS (Issued):**

1. US Patent No. 7,858,756, entitled "Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds" issued 12/28/2010. SM Owens, M Gunnell, Y Chi, FI Carroll, **R Henry**, E Peterson.
2. European Patent No. EP2032602, entitled “Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds” granted and published 03/27/13. SM Owens, M Gunnell, Y Chi, FI Carroll, **R Henry**, E Peterson.
3. US Patent No. 8,808,733, entitled “*Method of Controlled Drug Release from a Liposome Carrier”* issued 08/19/2014. D Fologea, G Salamo, **R Henry**, M Borrelli, P Chory.
4. US Patent No. 8,927,231, entitled “*A Separatome-Based Protein Expression and Purification Platform” issued* 01/06/2015. E Brune, R Beitle, M Ataai, P Bartlow, **R Henry**.
5. US Patent No. 9,023,353, entitled “Anti-(+)-Methamphetamine Monoclonal Antibodies” issued 05/05/2015. SM Owens, A Brown, **R Henry.**

**PATENTS (Pending):**

1. PCT/US2012/64087 filed 11/8/2012. Publication Number WO/2013/070872

*Title: Methods and Compositions for X-Ray Induced Release from pH Sensitive Liposomes.*  Published 5/16/2013 (Not yet nationalized)

1. PCT/US2014/12340

*Title: Heparin Affinity Tag and Applications Thereof.* Filed 1/21/2014. (Not yet nationalized or published).

**RESEARCHERS DIRECTED IN THE HENRY LABORATORY**

**For names, please see** [**www.uark.edu/ua/henrylab**](http://www.uark.edu/ua/henrylab)

Undergraduate researchers Directed: 23

Graduate Researchers Directed or Co-directed In My Laboratory: 7 PhD, 1 MS

Postdoctoral Researchers Directed: 5

**INVITED SPEAKER (Most Pertinent to Economic Development)**

-SEC Symposium on Driving a 21st Century Economy. Atlanta GA (Sept. 20-22, 2015)

Title: IGNITE: Industry Generating New Ideas and Technology through Education

-Arkansas IDeA Networks of Biomedical Research Excellence (February, 2006)

 Title: *Making Medicines to Treat Methamphetamine Abuse.*

-Arkansas Venture Forum (May, 2005).

Title: *Monoclonal Antibody Production in Plants: Making medical treatments 'affordable'*.

-Arkansas Biosciences Institute; Board of Directors Meeting (April, 2002).

Title: *Using tobacco to treat drug abuse.*

-Business Ventures Group at Univ. of Arkansas for Medical Sciences (July, 2001).

Title: *Plant-based production of antibody therapies to treat Methamphetamine abuse.*

**INVITED SPEAKER (Selected Scientific Talks):**

-European Research Conference on Protein Targeting (September, 2001).

Title: *SRP and Oxa1 homologues in chloroplasts; components of a novel posttranslational targeting pathway.*

-University of California SanFrancisco (November, 2001).

Title: *Posttranslational protein targeting by a chloroplast signal recognition particle.*

-Cornell University (March, 2002).

Title: *Protein targeting by a chloroplast signal recognition particle; what pure components reveal.*

-University of California Davis (May, 2002).

Title: *Protein targeting by a chloroplast signal recognition particle: Defining the targeting-translocation interface*.

-Ohio State University (January, 2003).

Title: *Protein interactions at the protein targeting-translocation interface*.

-University of Stockholm, Stockholm Sweeden (May, 2003).

Title: *Protein targeting to the thylakoid membrane by a chloroplast signal recognition particle; Protein interactions at the membrane interface.*

-13th International Photosynthesis Conference, Montreal Canada (Sept. 2004)

Title: *SRP-based protein targeting to the ALB3 translocase in thylakoid membranes.*

-Gordon Research Conference on ‘Protein Transport Across Cell Membranes’ (June, 2005)

Title: *Protein Interactions in Protein Targeting by a Chloroplast Signal Recognition Particle.*

-Laboratory of Plant Development, CEA Cadarache, Marseille, France (October, 2006)

Title: *Targeting of LHCs to the chloroplast thylakoid membrane by a chloroplast SRP and its receptor.*

-Conference on Nanotechnology in Healthcare, Rockefeller Institute (January 7-10, 2009).

 *Title: Design of liposome-encased quantum dots for drug delivery and release.*

-International Summer School of Neurology, Eforie Nord, Romania (July 4-7, 2011)

Title: Treating Drug Abuse With Neuroprotective Antibody Medications

-Department of Energy (BES Division), Gaithersburg, MD (October 19-21, 2015)

 Title: Structure and Function of a Chloroplast Signal Recognition Particle.

-Kansas State University, Div. of Biology, Manhattan, KS (October 23, 2015)

Title: Signal Recognition Particle: Adapting to Life In the Chloroplast

**FEDERAL GRANT FUNDING**

**CURRENT SUPPORT at UA:**

DE-FG02-01ER15161 (**Henry, PI**; S Kumar and C. Heyes, CoIs) (08/2016 – 07/2019)

**Department of Energy**($500,000 total)

Title: Protein Targeting to the Chloroplast Thylakoid Membrane: Structure of a chloroplast signal recognition particle.

The goal of this work is to understand the structure-based mechanism by which a chloroplast signal recognition particle is able to function in post-translational targeting and insertion of thylakoid membrane proteins.

**COMPLETED SUPPORT at UA:**

**Department of Energy (DOE),** "Protein Targeting to the Chloroplast Thylakoid Membrane: Structure of a chloroplast signal recognition particle." $250,000 for 3 years (8/2013 to 7/2016),  PI: Dr. Ralph Henry; Co-PIs: [Dr. T.K.S. Kumar](http://chemistry.uark.edu/1719.htm) and [Dr. Robyn Goforth](http://biology.uark.edu/1434.htm).

**US Food and Drug Administration, “**The Impact of Graphene-based Nanomaterials on Public Health: Strategy for assessing and understanding nanomaterial toxicity” $119,175 total (10/2014 – 5/2016), PI: Dr. Ralph Henry; Co-PIs: Dr D McNabb and R Barebote

**National Institutes of Health (NIH),** " COBRE Center for Protein Structure and Function Phase III." $375,000 total for 5 years (09/2010 – 05/2015) to support the Protein and Peptide Production Core to support parent grant.  PI: Millitt; Henry is PI and Director of the Protein Production Core.

**Department of Energy (DOE),** "Protein Targeting to the Chloroplast Thylakoid Membrane: Structure of a chloroplast signal recognition particle." $495,000 for 3 years (8/2010 to 7/2013),  PI: Dr. Ralph Henry; Co-PIs: [Dr. T.K.S. Kumar](http://chemistry.uark.edu/1719.htm) and [Dr. Robyn Goforth](http://biology.uark.edu/1434.htm).

**National Institutes of Health (NIH),** COBRE: "[Center for Protein Structure and Function](http://protein.uark.edu/)." Administrative Supplement for: "Exploring Novel Strategies to Prevent and Treat Viral  Infection." $854,803 for 2 years (8/09 to 7/11), PI: [Dr. Frank Millett](http://chemistry.uark.edu/1721.htm); Co-PIs: [Dr. Yuchun Du](http://biology.uark.edu/1874.htm), [Dr. T.K.S. Kumar](http://chemistry.uark.edu/1719.htm), and [Dr. Robyn Goforth](http://biology.uark.edu/1434.htm)**;** Dr. Ralph Henry, mentor.([Press Release](http://newswire.uark.edu/article.aspx?id=13214) in University of Arkansas' Newswire.)

**Department of Energy (DOE),** "Protein Targeting to the Chloroplast Thylakoid Membrane: Structure of a chloroplast signal recognition particle." $450,000 for 3 years (8/07 to 7/10),  PI: Dr. Ralph Henry; Co-PIs: [Dr. T.K.S. Kumar](http://chemistry.uark.edu/1719.htm) and [Dr. Robyn Goforth](http://biology.uark.edu/1434.htm). ([Press Release](http://newswire.uark.edu/article.aspx?id=11749) in University of Arkansas' Newswire.)

**Howard Hughes Medical Institute Undergraduate Science Education (HHMI),** "Undergraduate Research Center in Nanobiology." $1,501,315 for 4 years (9/06 to 8/10), PI: [Dr. Donald Bobbitt](http://chemistry.uark.edu/1230.htm); Co-PIs: [Dr. Gregory Salamo](http://www.uark.edu/depts/physics/faculty/index.php?name=salamo), [Dr. David Paul](http://chemistry.uark.edu/1232.htm), [Dr. Roger Koeppe](http://chemistry.uark.edu/1311.htm), Dr. Ralph  Henry. ([Press Release](http://newswire.uark.edu/article.aspx?id=9335) in University of Arkansas' Newswire.)

**National Science Foundation (NSF),** "Efficient Bioseparation by Intertwining Strain,  Chromatography and Affinity Tail Design." $494,602 for 3 years (5/06 to 4/09), PI: [Dr. Bob Beitle](http://www.engr.uark.edu/directory/562.php); Co-PI: Dr. Ralph Henry. ([Press Release](http://newswire.uark.edu/article.aspx?id=9235) in University of Arkansas' Newswire.)

**National Institutes of Health (NIH),** COBRE: "[Center for Protein Structure and Function](http://protein.uark.edu/)."  $10,200,000 for 5 years (10/05 to 9/10), PI: [Dr. Frank Millett](http://chemistry.uark.edu/1721.htm); Dr. Robyn Goforth is  Subproject-PI for cornerstone project (one of five featured in COBRE grant) titled "Protein  Targeting" along with [Dr. T.K.S. Kumar](http://chemistry.uark.edu/1719.htm) (Co-PI); Dr. Ralph Henry, mentor. ([Press Release](http://newswire.uark.edu/article.aspx?id=12539) in  University of Arkansas' Newswire.)

**Department of Energy (DOE),** "Protein Targeting to the Chloroplast Thylakoid Membrane:  Structure of a chloroplast signal recognition particle." $360,000 for 3 years (8/04 to 7/07),  PI: Dr. Ralph Henry; Co-PI: Dr. Chin Yu.

**National Institute on Drug Abuse (NIDA/NIH),** Development of "Therapeutic  Methamphetamine Antibodies from Plants." $1,242,211 for 5 years (9/01 to 8/06). PI: Dr. Ralph Henry; Co-PIs for this project of the program grant are Dr. Christine Farrance and [Dr. Joshua Sakon](http://chemistry.uark.edu/1724.htm) (U of A). [Dr. Mike Owens](http://pharmtox.uams.edu/owens) (UAMS) is the PI for the Program Project titled  "Preclinical Testing of Antibody Therapy for (+)METH Abuse" (total $5,522,972).

**Department of Energy (DOE),** "Protein Targeting to the Chloroplast Thylakoid Membrane:  Structure of a chloroplast signal recognition particle." $288,000 for 3 years (8/01 to 7/04),  PI: Dr. Ralph Henry; Co-PI: [Dr. Joshua Sakon](http://chemistry.uark.edu/1724.htm).

**National Institutes of Health (NIH),** COBRE: "[Center for Protein Structure and Function](http://protein.uark.edu/)." $9,631,312 for 5 years (10/00 to 9/05). PI: [Dr. Frank Millett](http://chemistry.uark.edu/1721.htm); Dr. Ralph Henry is PI for  cornerstone project (one of five featured in COBRE grant) titled "Protein Targeting" along with [Dr. Joshua Sakon](http://chemistry.uark.edu/1724.htm) (Co-PI). ([Press Release](http://newswire.uark.edu/article.aspx?id=12982) in University of Arkansas' Newswire.)

**National Science Foundation (NSF)**, "Molecular and Biological Engineering of Plant-derived Antibodies." $498,920 ($997,840 with matching funds from the state of Arkansas) for 2 years beginning July 1999. PI: [Dr. Mike Owens](http://pharmtox.uams.edu/owens) (UAMS); Co-PIs: Dr. Ralph Henry and [Dr. Brad Murphy](http://experts.uark.edu/details.php?id=832)(U of A). U of A's portion of the grant $247,000 from NSF (plus an additional $247,000 from state match.)

**National Science Foundation (NSF),** "Function of a chloroplast signal recognition particle in protein targeting and integration." $331,500 for 3 years (8/98 to 7/01). PI: Dr. Ralph Henry.

**Support from NIH/NIDA to InterveXion Therapeutics, LLC**

**Current**

Grant Number: U01 DA035511

Project Title: A Methamphetamine Conjugate Vaccine: From Manufacturing to IND

Total Amount: $9,552,837 (anticipated), $3,606,802 (awarded to date)

Principal Investigators: Misty Stevens (Contact), S. Michael Owens

Co-Investigators: **Ralph Henry**, R. Barry Holtz, W. Brooks Gentry

Grant Number: U01 DA037593

Project Title: Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb

Total Amount: $5,012,836 (anticipated), $1,287,478 (awarded to date)

Principal Investigators: Misty Stevens (Contact), W. Brooks Gentry

Co-Investigators: **Ralph Henry**, R. Barry Holtz, S. Michael Owens

**Completed**

Grant Number: R42 DA017596

Project Title: Development of Plant Derived Antibodies for Drugs Abuse

Total Amount: $3,148,978

Principal Investigator: R. Barry Holtz

Co-Investigators: **Ralph Henry**, W. Brooks Gentry, S. Michael Owens

Grant Number: RC2 DA028915

Project Title: Chimeric anti-Methamphetamine Monoclonal Antibody for Treating Stimulant Toxicity

Total Amount: $3,964,137

Principal Investigators: W. Brooks Gentry and R. Barry Holtz (Contact)

Co-Investigators: **Ralph Henry**, S. Michael Owens, Misty Stevens

Grant Number: R01 DA031944

Project Title: First Human Studies of a Chimeric Anti-Methamphetamine Monoclonal Antibody

Total Amount: $3,119,258

Principal Investigator: W. Brooks Gentry

Co-Investigators: **Ralph Henry**, R. Barry Holtz, S. Michael Owens, Misty Stevens

**PEER-REVIEWED PUBLICATIONS** (in reverse chronological order)

Links to these publications can be found at: <http://www.uark.edu/ua/henrylab/>)

1. Henderson R, F Gao, S Jayanthi, A Kight, P Sharma, R Goforth, C Heyes, **RL Henry**, and TKSuresh Kumar (2016). Domain Organization in the 54-kDa Subunit of the hloroplast Signal Recognition Particle. **Biophysical Journal** 111(6):1151-62. PMID: 276533474
2. Morris J, S Jayanthi, R Langston, A Daily, A Kight, D McNabb, **RL Henry**, and TKS Kumar (2016). Heparin-binding peptide as a novel affinity tag for purification of recombinant proteins. **Protein Expression and Purification**. 126:93-103 PMID 27235575
3. Gao F, AD Kight, R Henderson, S Jayanthi, P Patel, M Murchison, P Sharma, RL Goforth, TKS Kumar, **RL Henry**,and CD Heyes (2015) Regulation of Structural Dynamics within a Signal Recognition Particle Promotes Binding of Protein Targeting Substrates. ***J Biol Chem*** 290(25):15462-74. PMID: 25918165.
4. Stevens MW, **RL Henry**, SM Owens, R Schutz, WB Gentry (2014). First Human Study of a Chimeric Anti-Methamphetamine Monoclonal Antibody in Healthy Volunteers. ***MAbs*;** 6(6):1649-56. PMID: 25252196
5. Haley R, M Fruchtl, E Brune, A Mohammad, **RL Henry**, R Beitle(2014). A Redesigned Escherichia coli Triosephosphate Isomerase Restores Growth Properties in a Bacterial Strain Useful for Immobilized Metal Affinity Chromatography (IMAC). ***J Biotech***(188):48-52*.*
6. Stevens MW, Tawney RL, West CM, Kight AD, **Henry RL**, Owens SM, Gentry WB. (2014) Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use. **mAbs** 6(2):547-55. PMID: 24492290; PubMed Central PMCID: PMC3984342.
7. Krueger E, R Al Faouri, D Fologea, **RL Henry**, D Straub, G Salamo (2013). A model for the hysteresis observed in gating of lysenin channels. doi:pii: S0301-4622(13)00165-8. 10.1016 **J Biophys Chem** [Epub ahead of print] PMID: 24075493
8. Upreti M, A Jamshidi-Parsian, S Apana, MS Berridge, DA Fologea, NA Koonce, **RL Henry**, RJ Griffin (2012) Radiation-induced Galectin-1 by endothelial cells: A promising molecular target for preferential drug delivery to the tumor vasculature. **J Mol Med** (Berl). PMID: 23090010
9. Fologea D, R Al Faori, E Krueger, YI Mazur, M Kern, M Williams, A Mortazavi, **RL Henry,** GJ Salamo(2011). Potential Analytical Applications of Lysenin Channels for Detection of Multivalent Ions.  [**Anal Bioanal Chem.** 401(6): 1871-1879.](http://www.springerlink.com/content/f37174m1u2n41611/fulltext.pdf)
10. D Fologea; E Krueger; Yuriy Mazur; C Stith, Y Okuyama, **RL Henry**; GJ Salamo (2011). Bi-stability, Hysteresis, and Memory of Voltage-gated Lysenin Channels. **BBA Biomembranes**. 1808(12):2933-9. PMID: 21945404
11. D Fologea, R Al Faori, E Krueger, YI Mazur, M Kern, M Williams, A Mortazavi, RL Henry, GJ Salamo (2010) Potential Analytical Applications of Lysenin Channels for Detection of Multivalent Ions. **Anal Bioanal Chem.** 401:1871-1879. PMID: 21818682
12. Lewis, NE, NJ Marty, KM Kathir, D Rajalingam, AD Kight, A Daily, TKS Kumar, **RL Henry**, RL Goforth (2010). A Dynamic CpSRP43-Albino3 Interaction Mediates Translocase Regulation of cpSRP Targeting Components. [**J Biol Chem** 285(44): 34220-34230*.*](http://www.jbc.org/content/285/44/34220.full.pdf%2Bhtml) PMID: 20729200
13. **Henry, RL** (2010) SRP: Adapting To Life In The Chloroplast. [**Nature Structural & Molecular Biology** 17(6): 676-677.](http://www.nature.com/nsmb/journal/v17/n6/pdf/nsmb0610-676.pdf) PMID: 20520661
14. Fologea D, E Krueger, R Al Faori, R Lee, YI Mazur, **RL Henry**, M Arnold, GJ Salamo (2010). Multivalent Ions Control the Transport through Lysenin Channels. [**Biophysical Chemistry** 152(1): 40-45.](http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TFB-50P9H3X-2&_user=1942757&_coverDate=11%2F30%2F2010&_rdoc=6&_fmt=high&_orig=browse&_origin=browse&_zone=rslt_list_item&_srch=doc-info(%23toc%235222%232010%23998479998%232591770%23FLA%23display%23Volume)&_cdi=5222&_sort=d&_docanchor=&_ct=23&_acct=C000055513&_version=1&_urlVersion=0&_userid=1942757&md5=d359f022d89d214a7a6e98d89cd99225&searchtype=a) PMID: 20724059.
15. Tiwari N, L Woods, A Kight, R Haley, R Goforth, K Clark, M Ataai, **RL** **Henry**, R Beitle (2010). Identification and characterization of native proteins of *Escherichia coli* BL-21 that display affinity towards Immobilized Metal Affinity Chromatography and Hydrophobic Interaction Chromatography Matrices. **Protein Expression and Purification,** 70(2):191-5
16. Fologea D, E Krueger, R Lee, M Naglak, Y Mazur, **RL Henry**, G Salamo (2009). Controlled Gating of Lysenin Pores. **Biophysical Chemistry** 146, pp. 25-29.
17. Marty, NJ, R Dakshinamurthy, AD Kight, NE Lewis, D Fologea, TKS Kumar, **RL** **Henry**, RL Goforth (2009). **The membrane-binding motif of chloroplast signal recognition particle receptor (cpFtsY) regulates GTPase activity. J. Biol. Chem** 284(22), 14891-14903
18. Ananthamurthy, K, KM Kathir, A Kight, RL Goforth, **RL Henry**, TKS Kumar (2008). 1H, 13C and 15N Resonance Assignments of the C-terminal Chromo domain of the chloroplast signal recognition particle. **J Biomolecular NMR Assignments** 2(1):37-39.
19. KM Kathir, D Rajalingam, V Sivaraja, A Kight, RL Goforth, C Yu, **RL Henry**, TKS Kumar (2008). Assembly of Chloroplast Signal Recognition Particle involves Structural Rearrangement in cpSRP43 **J Mol Biol** 381(1):49-60
20. Lewis, P, I Fritch, RE Gawley, **RL Henry**, A Kight, JO Lay, R Liyanage, J McLachlin (2008). Dynamics of saxitoxin binding to saxiphilin c-lobe reveals conformational change. **Toxicon**. 51:208-217.
21. **Henry, RL**, RL Goforth, D Scheunemann (2007). Chloroplast SRP/FtsY and Alb3 in Protein Integration into the Thylakoid Membrane; In **The Enzymes** *(Volume 25; Molecular Machines Involved In Protein Transport Across Cellular Membranes), Ross E. Dalbey, Carla Koehler, and Fuyuhiko Tamanoi Editors.*
22. Tzvetkova-Chevolleau T, C Hutin, LD. Noël, RL Goforth, JP Carde, S Caffarri, I Sinning, M Groves, JM Teulon, NE Hoffman, **RL Henry**, M Havaux and L Nussaume(2007). Canonical SRP components can be bypassed for post-translational protein targeting in chloroplasts. **Plant Cell**. 19(5):1635-48.
23. Peterson E, MG Gunnell, Y Che, RL Goforth, FI Carroll, **RL Henry**, H Liu, SM Owens (2007). Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse. **J Pharm. Exp. Therap.** 322(1):30-9.
24. Peterson E, SM Owens, **RL Henry** (2006). Monoclonal Antibody Form and Function: Manufacturing the Right Antibodies for Treating Drug Abuse. ***AAPS Journal***.  8(2)
25. Sivaraja, V., T.K.S. Kumar, P.S.T. Leena, A. Chang, C. Vidya, R.L. Goforth, D. Rajalingam, K. Arvind, J. Ye, J. Chou, **RL Henry** and C Yu. (2005) Three-Dimensional Solution Structures of the Chromo Domains of cpSRP43. **J Biol Chem**, 280(50):41465-71.
26. Cai, Y, M. Moore, R. Goforth, **RL Henry**, and R. Beitle. (2004) Genomic data for alternate production strategies: Identification of major contaminating species for Co(II) immobilized metal affinity chromatography. **Biotechnology and Bioengineering**, 88(1):77-83.
27. Wang Q, RW Sullivan, A Kight, **RL Henry**, AM Jones, KL Korth. (2004) Deletion of the chloroplast-localized THYLAKOID FORMATION1 gene product in Arabidopsis thaliana leads to deficient thylakoid formation and variegated leaves. **Plant Physiol**. 136(3):3594-604.
28. Goforth RL, EC Peterson, J Yuan, MJ Moore, AD Kight, MB Lohse, JSakon, and **RL Henry** (2004). Regulation of the GTPase cycle in posttranslational signal recognition particle based protein targeting involves cpSRP43. **J Biol Chem**. 279(41):43077-84.
29. Kuhn, A, R Stuart, **RL Henry**, and R Dalbey (2003). The Alb3/Oxa1/YidC protein family: membrane localized chaperones facilitating membrane protein insertion? **Trends Cell Biol.** 13(10):510-6.
30. Moore, MJ, RL Goforth, H Mori, and **RL Henry** (2003). Functional interaction of chloroplast SRP/FtsY with the ALB3 translocase in thylakoids: substrate not required. **J Cell Biol**. 162(7):1245-54.
31. Yuan J, A Kight, R Goforth, M Moore, EC Peterson, J Sakon, and **RL Henry** (2002). ATP Stimulates SRP/FtsY-Supported Protein Integration in Chloroplasts. **J Biol Chem**. 277 (35): 32400-4.
32. Jiang F, Yi L, M Moore, M Chen, T Rohl, KJ van Wijk, JW de Gier, **RL Henry**, R Dalbey (2002). Chloroplast YidC homologue Albino3 can functionally complement the bacterial YidC depletion strain and promote membrane insertion of both bacterial and chloroplast thylakoid proteins. **J Biol Chem**. 277(22):19281-8.
33. Woolhead, C, S Thompson, M Moore, C Tissier, A Mant, A Rodger, **RL Henry**, and C Robinson (2001). Dinstinct Albino3-dependent and –independent pathways for thylakoid membrane protein insertion. **J Biol. Chem**. 276(44):40841-6.
34. Mant, A, CA Woolhead, M Moore **RL Henry**, C Robinson (2001). Insertion of PsaK into the thylakoid membrane in a ‘horse-shoe’ conformation occurs in the absence of signal recognition particle, nucleoside triphosphates or functional Alb 3. **J Biol. Chem**. 276(39):36200-6.
35. Eichacker, L. and **RL Henry**. (2001) Function of a chloroplast SRP in thylakoid protein export. **Biochim Biophys Acta.** 1541(1-2):120-34.
36. Tu, CJ, EC Peterson, **RL Henry**, NE Hoffman (2000). The L18 domain of LHCP binds to the cpSRP43 subunit of a chloroplast signal recognition particle. **J Biol. Chem**. 275:13187-90.
37. DeLille, J, EC Peterson, T Johnson, M Moore, A Kight, **RL Henry** (2000). A novel recognition element in LHCP enables post-translational binding by a chloroplast signal recognition particle. **Proc Natl Acad Sci**. 97: 1926-1931.
38. Sehnke, PC, **RL Henry**, KC Cline, RJ Ferl (2000) Interaction of a Plant 14-3-3 protein with the signal peptide of a thylakoid-targeted chloroplast precursor protein and the presence of 14-3-3 isoforms in the chloroplast stroma. **Plant Physiol** 122, 1-7.
39. Moore, M, MS Harrison, EC Peterson, **RL Henry** (2000). Chloroplast Oxa1p Homologue, Albino3, Functions in Post-translational Integration of the Light Harvesting Chlorophyll-binding Protein into Thylakoid membranes. **J Biol. Chem**. 275: 1529-1532.
40. High, S, **RL Henry**, RM Mould, Q Valent, S Meacock, K Cline, JC Gray, J Luirink. (1997) Chloroplast SRP54 interacts with a specific subset of thylakoid precursors. **J Biol. Chem**. 272: 11622-11628.
41. **Henry, RL**, M Carrigan, M McCaffery, X Ma, K Cline. (1997) Targeting determinants and proposed evolutionary basis for the Sec and the Delta pH protein transport systems in chloroplast thylakoid membranes. **J Cell Biol**., 136(4), 823-832.
42. Cline, K, and **RL Henry**. (1996) Import and sorting of chloroplast proteins. **Annual Review of Cell and Developmental Biology**, Vol. 12 (Spudich, Gerhart, McNight, and Scheckman, ed.) pp 1-26. Annual Reviews Inc. U.SA.
43. Li, X, **RL Henry**, J Yuan, K Cline, NE Hoffman. (1995) A chloroplast homologue of the signal recognition particle subunit SRP54 is involved in the post-translational integration of a protein into thylakoid membranes. **Proc. Natl. Acad. Sci.** 92, 3789-3793.
44. **Henry, RL**, A Kapazoglou, M McCaffery, K Cline.(1994) Differences between lumen targeting domains of chloroplast transit peptides determine pathway specificity for thylakoid transport. **J. Biol. Chem**. 269, 10189-10192.
45. Yuan, J, **RL Henry**, M McCaffery, K Cline. (1994) SecA homologue in protein transport within chloroplasts: Evidence for endosymbiont-derived sorting. **Science** 266 (5186), 796-798.
46. Cline, K, **RL Henry**, C Li, J Yuan. (1993) Multiple pathways for protein transport into or across the thylakoid membrane. **EMBO** 12 (11), 4105-4114.
47. Yuan, J, **RL Henry**, K Cline. (1993) Stromal factor plays an essential role in protein integration into thylakoids that cannot be replaced by unfolding or by heat shock protein Hsp 70. **Proc. Natl. Acad. Sci.** 90, 8552-8556.
48. **Henry, RL**, LJ Takemoto, J Murphy, GL Gallegos, JA Guikema. (1992) Development and use of domain-specific antibodies in a characterization of the large subunits of soybean photosystem 1. **Plant Physiology and Biochemistry** 30(3), 357-364.
49. **Henry, RL**, T Armbrust, GL Gallegos, JA Guikema. (1992) Characterization of photosystem 1 chlorophyll a/b-binding apoprotein accumulation in developing soybean using type-specific antibodies. **Plant Physiology and Biochemistry** 30(3), 347-356.
50. Cai,X, **RL Henry**, JA Guikema, PP Wong. (1992) Anti-peptide antibodies that can distinguish specific subunit polypeptides of glutamine synthetase from bean (Phaseolus vulgaris L.). **Plant Physiology** 98, 402-405.
51. **Henry, RL**, PD Green, PP Wong, JA Guikema. (1990) Binding of isolated plant lectin by rhizobia during episodes of zero-gravity obtained by parabolic flight. **Plant Physiology** 92, 262-264.